MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 12, 2024 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Invitae Corporation
- Interventions being studied
- Diagnostic Test: Personalized Cancer Monitoring (PCM)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Stated ability to give informed consent by participant. 2. Stated health status of participant as healthy enough to provide Biological Material. 3. Individuals diagnosed with solid cancer of any type, including but not limited to colorectal, non-small cell lung, breast, ovarian and bladder cancers, regardless of the length of time since diagnosis and regardless of previous therapies. 4. Participant is of any biological sex and \>18 years of age 5. Participant has not undergone a blood transfusion within the previous three weeks
1. Participants who are deemed medically unstable 2. Participants who are deemed to be "difficult to draw" blood from. 3. Participants who are \<18 years of age 4. Participants diagnosed with CNS cancers, sarcomas or hematologic malignancies such as leukemia or lymphoma . 5. Participants with more than one primary cancer 6. Participants with FFPE slides older than 10 years 7. Participants who are pregnant 8. Any other reason that, in the Investigator's judgment, that would preclude the participant from being able to participate in the study 9. Participants for which a pathology report is not available
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Columbus Regional HealthColumbus, Indiana
- Onslow RadiationJacksonville, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 12, 2024. Always confirm current availability with the study team.